PriceTargets.com logo

Sage Therapeutics - SAGE Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $8.13
  • Forecasted Upside: -6.30%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 9 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$8.68 As of 07/31/2025 01:00 AM ET
+0 (0.00%)
Get New Sage Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SAGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SAGE

Analyst Price Target is $8.13
▼ -6.30% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Sage Therapeutics in the last 3 months. The average price target is $8.13, with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a -6.30% upside from the last price of $8.68.

This chart shows the closing price for SAGE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 10 investment analysts is to reduce stock in Sage Therapeutics. This rating has held steady since June 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 15 hold ratings
  • 2 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 16 hold ratings
  • 2 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 17 hold ratings
  • 2 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 15 hold ratings
  • 2 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 14 hold ratings
  • 1 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 13 hold ratings
  • 1 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 11 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/8/2025ScotiabankDowngradeStrong-Buy ➝ Hold$12.00 ➝ $9.20
6/20/2025Robert W. BairdBoost TargetNeutral ➝ Neutral$7.00 ➝ $9.00
6/17/2025Piper SandlerDowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.50
6/17/2025Truist FinancialSet TargetHold ➝ Hold$8.00 ➝ $9.00
6/17/2025HC WainwrightReiterated RatingNeutral ➝ Neutral$12.00
6/17/2025Canaccord Genuity GroupBoost TargetHold ➝ Hold$8.00 ➝ $8.50
6/16/2025Needham & Company LLCReiterated RatingHold ➝ Hold
4/25/2025Needham & Company LLCReiterated RatingHold ➝ Hold
3/11/2025Bank of AmericaInitiated CoverageUnderperform$5.00
2/12/2025ScotiabankLower TargetSector Outperform ➝ Sector Outperform$14.00 ➝ $12.00
2/12/2025WedbushReiterated RatingNeutral ➝ Neutral$6.00 ➝ $6.00
2/12/2025Canaccord Genuity GroupLower TargetHold ➝ Hold$9.00 ➝ $8.00
2/12/2025Needham & Company LLCReiterated RatingHold ➝ Hold
2/12/2025HC WainwrightReiterated RatingNeutral ➝ Neutral$14.00 ➝ $12.00
1/2/2025Piper SandlerLower TargetOverweight ➝ Overweight$26.00 ➝ $9.00
12/16/2024Stifel NicolausLower TargetHold ➝ Hold$10.00 ➝ $6.00
11/21/2024TD CowenLower TargetHold ➝ Hold$10.00 ➝ $9.00
11/21/2024Royal Bank Of CanadaUpgradeUnderperform ➝ Sector Perform$4.00 ➝ $4.00
11/20/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$14.00 ➝ $14.00
11/20/2024Needham & Company LLCReiterated RatingHold
10/30/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$17.00 ➝ $14.00
10/30/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$52.00 ➝ $26.00
10/30/2024OppenheimerLower TargetMarket Perform ➝ Market Perform$9.00 ➝ $8.00
10/30/2024Truist FinancialLower TargetHold ➝ Hold$13.00 ➝ $8.00
10/30/2024HC WainwrightLower TargetNeutral ➝ Neutral$25.00 ➝ $14.00
10/30/2024Needham & Company LLCReiterated RatingHold
10/17/2024Needham & Company LLCReiterated RatingHold
10/10/2024Raymond James FinancialReiterated RatingMarket Perform
10/9/2024Bank of AmericaLower TargetUnderperform ➝ Underperform$11.00 ➝ $6.00
10/9/2024WedbushLower TargetNeutral ➝ Neutral$9.00 ➝ $8.00
10/9/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
10/9/2024Robert W. BairdLower TargetNeutral ➝ Neutral$13.00 ➝ $9.00
10/8/2024Needham & Company LLCReiterated RatingHold
10/4/2024Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform$10.00 ➝ $4.00
8/14/2024Truist FinancialLower TargetHold ➝ Hold$18.00 ➝ $13.00
8/6/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$12.00 ➝ $10.00
8/2/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
8/1/2024Needham & Company LLCReiterated RatingHold
7/30/2024TD CowenDowngradeBuy ➝ Hold$16.00 ➝ $10.00
7/26/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$19.00 ➝ $11.00
7/25/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$19.00 ➝ $17.00
7/25/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
7/25/2024Robert W. BairdLower TargetNeutral ➝ Neutral$15.00 ➝ $13.00
7/25/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$18.00 ➝ $12.00
7/24/2024Needham & Company LLCReiterated RatingHold
7/19/2024MizuhoLower TargetNeutral ➝ Neutral$18.00 ➝ $16.00
7/12/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$23.00 ➝ $18.00
7/2/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
6/28/2024Needham & Company LLCReiterated RatingHold
6/20/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$28.00 ➝ $23.00
6/12/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
6/11/2024Robert W. BairdReiterated RatingNeutral ➝ Neutral$15.00 ➝ $15.00
6/11/2024Needham & Company LLCReiterated RatingHold
5/29/2024Baird R WUpgradeHold
5/29/2024Robert W. BairdInitiated CoverageNeutral$15.00
5/29/2024CitigroupInitiated CoverageSell$8.00
5/1/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$29.00 ➝ $28.00
4/26/2024HC WainwrightLower TargetNeutral ➝ Neutral$28.00 ➝ $25.00
4/26/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$28.00 ➝ $19.00
4/26/2024Truist FinancialLower TargetHold ➝ Hold$22.00 ➝ $18.00
4/26/2024Royal Bank Of CanadaLower TargetSector Perform ➝ Sector Perform$26.00 ➝ $15.00
4/26/2024MizuhoLower TargetNeutral ➝ Neutral$20.00 ➝ $18.00
4/26/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$21.00 ➝ $17.00
4/25/2024Needham & Company LLCReiterated RatingHold
4/18/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$34.00 ➝ $19.00
4/18/2024OppenheimerLower TargetMarket Perform ➝ Market Perform$25.00 ➝ $17.00
4/18/2024Needham & Company LLCReiterated RatingHold
4/18/2024TD CowenLower TargetBuy ➝ Buy$30.00 ➝ $16.00
4/17/2024WedbushReiterated RatingNeutral ➝ Neutral$24.00
4/17/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$28.00
4/17/2024Bank of AmericaDowngradeNeutral ➝ Underperform$24.00 ➝ $14.00
3/26/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$24.00 ➝ $29.00
2/28/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$20.00 ➝ $22.00
2/15/2024HC WainwrightBoost TargetNeutral ➝ Neutral$25.00 ➝ $28.00
2/15/2024Royal Bank Of CanadaBoost TargetSector Perform ➝ Sector Perform$21.00 ➝ $26.00
12/18/2023Stifel NicolausLower TargetHold ➝ Hold$22.00 ➝ $20.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$21.00
11/8/2023Royal Bank Of CanadaLower TargetSector Perform ➝ Sector Perform$22.00 ➝ $21.00
11/8/2023WedbushBoost TargetNeutral ➝ Neutral$21.00 ➝ $22.00
10/13/2023The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$22.00 ➝ $25.00
9/8/2023Bank of AmericaLower TargetNeutral ➝ Neutral$25.00 ➝ $24.00
9/7/2023Royal Bank Of CanadaLower TargetSector Perform ➝ Sector Perform$25.00 ➝ $22.00
9/7/2023MizuhoBoost TargetNeutral ➝ Neutral$19.00 ➝ $20.00
9/1/2023ScotiabankBoost Target$24.00 ➝ $27.00
8/9/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$49.00 ➝ $20.00
8/8/2023TD CowenLower TargetOutperform ➝ Outperform$105.00 ➝ $28.00
8/8/2023OppenheimerLower TargetMarket Perform ➝ Market Perform$24.00 ➝ $20.00
8/8/2023Truist FinancialLower TargetHold ➝ Hold$40.00 ➝ $20.00
8/8/2023MizuhoLower TargetNeutral ➝ Neutral$45.00 ➝ $19.00
8/8/2023HC WainwrightLower Target$50.00 ➝ $27.00
8/8/2023The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$75.00 ➝ $22.00
8/8/2023Needham & Company LLCDowngradeBuy ➝ Hold
8/8/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$64.00 ➝ $21.00
8/8/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$64.00 ➝ $21.00
8/7/2023BarclaysLower Target$311.00 ➝ $294.00
8/7/2023Bank of AmericaDowngradeBuy ➝ Neutral$66.00 ➝ $25.00
8/7/2023Stifel NicolausDowngradeBuy ➝ Hold$60.00 ➝ $22.00
8/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$70.00
8/7/2023HC WainwrightReiterated RatingNeutral ➝ Neutral$50.00
8/7/2023WedbushDowngradeOutperform ➝ Neutral$51.00 ➝ $22.00
8/7/2023OppenheimerDowngradeOutperform ➝ Market Perform
8/7/2023Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform$71.00 ➝ $25.00
8/3/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$49.00
7/27/2023ScotiabankInitiated CoverageOutperform
6/15/2023Bank of AmericaBoost Target$61.00 ➝ $66.00
5/23/2023Bank of AmericaBoost Target$56.00 ➝ $61.00
5/3/2023VNET GroupReiterated RatingMaintains
5/3/2023Royal Bank Of CanadaBoost Target$60.00 ➝ $63.00
3/13/2023Royal Bank Of CanadaUpgradeSector Perform ➝ Outperform$40.00 ➝ $60.00
3/9/2023HC WainwrightReiterated RatingNeutral$50.00
2/17/2023HC WainwrightReiterated RatingNeutral$50.00
2/17/2023Needham & Company LLCReiterated RatingBuy$70.00
2/17/2023CitigroupBoost TargetNeutral$40.00 ➝ $46.00
2/17/2023MizuhoBoost TargetNeutral$37.00 ➝ $45.00
1/3/2023GuggenheimDowngradeBuy ➝ Neutral
12/6/2022JPMorgan Chase & Co.Lower TargetOverweight$92.00 ➝ $60.00
11/21/2022Morgan StanleyLower TargetEqual Weight$53.00 ➝ $50.00
11/11/2022GuggenheimLower TargetBuy$55.00 ➝ $48.00
11/9/2022BMO Capital MarketsLower TargetMarket Perform$43.00 ➝ $40.00
11/9/2022HC WainwrightLower TargetNeutral$55.00 ➝ $50.00
11/1/2022Loop CapitalInitiated CoverageHold$41.00
8/3/2022CitigroupLower Target$41.00 ➝ $40.00
8/2/2022Stifel NicolausLower Target$58.00 ➝ $56.00
7/11/2022Leerink PartnersLower TargetMarket Perform$50.00 ➝ $40.00
6/3/2022CitigroupBoost Target$41.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$85.00 ➝ $73.00
5/4/2022MizuhoLower Target$41.00 ➝ $37.00
3/31/2022Berenberg BankInitiated CoverageHold$37.00
3/10/2022Morgan StanleyLower TargetEqual Weight$61.00 ➝ $57.00
3/9/2022Truist FinancialLower TargetHold$60.00 ➝ $40.00
3/3/2022MizuhoLower TargetNeutral$44.00 ➝ $41.00
2/25/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$95.00 ➝ $64.00
2/25/2022Leerink PartnersLower TargetMarket Perform$60.00 ➝ $50.00
2/17/2022The Goldman Sachs GroupLower TargetBuy$96.00
1/6/2022Needham & Company LLCBoost TargetBuy$79.00 ➝ $85.00
12/20/2021Leerink PartnersLower TargetMarket Perform$70.00 ➝ $60.00
11/18/2021Needham & Company LLCReiterated RatingBuy$78.00
11/18/2021MizuhoLower TargetNeutral$52.00 ➝ $44.00
11/3/2021OppenheimerLower TargetOutperform$84.00 ➝ $80.00
11/3/2021HC WainwrightLower TargetNeutral$80.00 ➝ $55.00
11/2/2021Royal Bank Of CanadaLower TargetSector Perform$52.00 ➝ $48.00
11/2/2021GuggenheimUpgradeNeutral ➝ Buy$55.00
10/20/2021Needham & Company LLCInitiated CoverageBuy$84.00 ➝ $80.00
10/20/2021OppenheimerLower TargetPositive ➝ Outperform$100.00 ➝ $84.00
10/18/2021Leerink PartnersReiterated RatingMarket Perform
10/12/2021Morgan StanleyLower TargetEqual Weight$81.00 ➝ $78.00
10/7/2021Leerink PartnersReiterated RatingHold
10/6/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$100.00 ➝ $50.00
10/4/2021Stifel NicolausLower TargetBuy$95.00 ➝ $75.00
9/22/2021Needham & Company LLCInitiated CoverageBuy$84.00
8/4/2021Royal Bank Of CanadaLower TargetSector Perform$60.00 ➝ $55.00
8/4/2021HC WainwrightLower TargetNeutral$86.00 ➝ $80.00
6/16/2021Leerink PartnersLower TargetMarket Perform$90.00 ➝ $70.00
6/16/2021HC WainwrightReiterated RatingHold
6/16/2021Stifel NicolausLower TargetBuy$121.00 ➝ $95.00
6/16/2021William BlairDowngradeOutperform ➝ Market Perform$62.00
6/16/2021BMO Capital MarketsLower TargetPositive ➝ Market Perform$87.00 ➝ $73.00
6/16/2021CitigroupDowngradeBuy ➝ Neutral$101.00 ➝ $68.00
5/5/2021MizuhoLower TargetNeutral$81.00 ➝ $77.00
4/19/2021Morgan StanleyLower TargetEqual Weight$87.00 ➝ $81.00
4/12/2021MizuhoReiterated RatingHold$81.00
4/7/2021Piper SandlerInitiated CoverageOverweight$100.00
3/4/2021MizuhoReiterated RatingBuy ➝ Neutral$81.00
3/2/2021Morgan StanleyBoost TargetEqual Weight$83.00 ➝ $87.00
2/26/2021MizuhoDowngradeBuy ➝ Neutral$81.00
2/25/2021OppenheimerBoost TargetOutperform$90.00 ➝ $102.00
2/25/2021HC WainwrightBoost TargetNeutral$74.00 ➝ $86.00
2/25/2021HC WainwrightReiterated RatingNeutral$74.00 ➝ $86.00
2/1/2021Raymond James FinancialInitiated CoverageMarket Perform
1/22/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$95.00
1/19/2021WedbushBoost TargetOutperform$83.00 ➝ $98.00
1/4/2021GuggenheimUpgradeNeutral ➝ Buy
1/4/2021Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform$83.00 ➝ $86.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
5/9/2025
  • 14 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 6 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 9 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sage Therapeutics logo
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $8.68
Low: $8.68
High: $8.68

50 Day Range

MA: $8.88
Low: $8.68
High: $9.28

52 Week Range

Now: $8.68
Low: $4.62
High: $11.44

Volume

N/A

Average Volume

3,633,589 shs

Market Capitalization

$543.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Sage Therapeutics?

The following sell-side analysts have issued reports on Sage Therapeutics in the last year: Bank of America Corporation, Canaccord Genuity Group Inc., HC Wainwright, Needham & Company LLC, Piper Sandler, Robert W. Baird, Scotiabank, Stifel Nicolaus, Truist Financial Corporation, Wall Street Zen, and Wedbush.
View the latest analyst ratings for SAGE.

What is the current price target for Sage Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Sage Therapeutics in the last year. Their average twelve-month price target is $8.13, suggesting a possible downside of 6.3%. HC Wainwright has the highest price target set, predicting SAGE will reach $12.00 in the next twelve months. Bank of America Corporation has the lowest price target set, forecasting a price of $5.00 for Sage Therapeutics in the next year.
View the latest price targets for SAGE.

What is the current consensus analyst rating for Sage Therapeutics?

Sage Therapeutics currently has 1 sell rating and 9 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for SAGE.

What other companies compete with Sage Therapeutics?

Other companies that are similar to Sage Therapeutics include Vera Therapeutics, Aurinia Pharmaceuticals, Avadel Pharmaceuticals, Structure Therapeutics and Jyong Biotech. Learn More about companies similar to Sage Therapeutics.

How do I contact Sage Therapeutics' investor relations team?

Sage Therapeutics' physical mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 299-8380 and its investor relations email address is [email protected]. The official website for Sage Therapeutics is www.sagerx.com. Learn More about contacing Sage Therapeutics investor relations.